Novo's once-weekly insulin hope on par with daily injections, phase III trials show

Novo Nordisk has announced headline results from two late-stage studies of its once-weekly insulin treatment, insulin icodec, meeting both endpoints.

Photo: Novo Nordisk / PR

On Friday, Novo Nordisk announced clinical success with its once-weekly insulin icodec in two different studies, according to a press release.

The endpoints of both studies were to demonstrate the non-inferiority of weekly insulin icodec compared to existing daily treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs